TY  - JOUR
TI  - Generation of Induced Pluripotent Stem Cells from Patients with
Multiple Myeloma
AB  - Objective: Patient-specific induced pluripotent stem cells (iPSCs)
have potential in human disease modeling and regenerative medicine.
The in vitro phenotype of disease-specific iPSC-derived cells can
be used to bridge the knowledge gap between clinical phenotype
and molecular or cellular pathophysiology and to understand the
pathology of diseases, along with further applications, such as creating
new strategies for drug screening or developing novel therapeutic
agents. The aim of our study was to generate iPSCs from multiple
myeloma (MM) patients.
Materials and Methods: Mesenchymal stem cells (MSCs) isolated
from MM patients were induced for pluripotency via the Sendai virus.
Fibroblasts were used as a control. Microscopic analysis was performed
daily. For colony selection, live staining was done using alkaline
phosphatase staining. Reprogramming experiments were confirmed by
flow cytometry, immunofluorescence (IF) staining, and gene expression
analyses. To confirm the spontaneous differentiation potential, an in
vitro embryonic body (EB) formation assay was performed.
Results: Fibroblasts and MSCs obtained from MM patients were
reprogrammed using the Sendai virus, which contains reprogramming
vectors with the four Yamanaka factors, Oct3/4, Sox2, Klf4, and c-Myc.
Microscopic analysis revealed that the generated iPSCs possessed
classical embryonic stem cell-like morphological characteristics.
Reprogramming experiments further showed that both cell lines can
be reprogrammed up to the pluripotent stage, which was confirmed by
flow cytometry, IF staining, and gene expression analyses. Spontaneous
differentiation potential was confirmed by in vitro EB formation assays.
Conclusion: iPSCs have been successfully obtained from MM patients
for the first time. These cells could clarify the molecular mechanisms
behind this disease.
AU  - Karaoz, Erdal
AU  - BAŞARAN, İrem Yılmaz
DO  - 10.4274/tjh.galenos.2021.2020.0682
PY  - 2021
JO  - Turkish Journal of Hematology
VL  - 38
IS  - 4
SN  - 1300-7777
SP  - 254
EP  - 263
DB  - TRDizin
UR  - http://search/yayin/detay/508832
ER  -